Systemic inflammation at low doses: In animal models, even low doses or a single dose of semaglutide were shown to reduce TNF- and other inflammatory signals within hours of an inflammatory challenge Human trials suggest anti-inflammatory benefits at sub-weight loss (low) doses: Multiple trials (SUSTAIN, PIONEER, STEP, and others) show reductions in hsCRP and other inflammatory markers at low doses, in some datasets, only a portion of this effect is explained by changes in weight or blood sugar
They're signals that something in the system needs adjustment: your dose, your protein intake, your movement patterns, or the lifestyle factors quietly working against your goals
patients are covered by health insurance and would likely pay less for the drugs
S., Pistilli, E., Guerron, A